Based on the inspection and the review thereafter US-FDA has classified Suven facility at Suryapet as acceptable for manufacture and supply of intermediates for active pharmaceutical ingredients (API’s).
This is the second facility in Suven to have FDA acceptance and prior to this in 2007 Suven unit at Pashamylaram received the FDA acceptance for supply of API’s and intermediates.
So far Suven Life Sciences has filed 11 DMF's out of which 3 are on behalf of customers. With pending ANDA approvals Suven can supply the active pharmaceutical ingredients in addition to regulated intermediates for bulk API’s in the near future thus generating new revenues in due course of time.
Suven Life Sciences is a Hyderabad based Life Science Company, a Collaborative Research Partner (CRP) in Drug Discovery for a global Pharma major since 2006 is a pioneer in Contract Research and Manufacturing Services (CRAMS) since 1995 and Drug Discovery and Development Support Services (DDDSS) since 2005. Suven is engaged in discovering new chemical entities in Central Nervous System (CNS) therapeutic areas Viz: Alzheimer’s, Cognitive impairment, Dementia, Depression, Parkinson's disease and obesity which are at various phases of preclinical and clinical development.
For more information on Suven/ACT, please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;
